Introduction
============

Nasopharyngeal carcinoma (NPC) is prevalent in Southern China, and mainly affects the middle-aged population. NPC tends to present at an advanced stage at diagnosis, and has a relatively poor survival rate after diagnosis, because the primary anatomic site of the tumor is located in a silent area, and its symptoms are inconspicuous [@B1]. Despite the discovery of the very close association of EBV with NPC, the exact role of this virus in NPC development has remained not completely elucidated. EBV serological detection has been the most promising tool used in NPC screening. However, most studies on EBV antibodies have been conducted on the basis of the small pilot cross-sectional study of preliminary NPC screening due to the lake of data obtained from large-scale samples from NPC long-term follow-ups. In the present study, a total of 16,712 participants were enrolled between 2009 and 2010. Enzyme-linked immunosorbent assay (ELISA) for VCA/IgA and EBNA1/IgA were performed for all subjects, and the preliminary results of this serological screening were reported [@B2],[@B3]. A six-year follow-up survey was carried out up to the end of December 2015. The purpose of the present study was to evaluate the long-term diagnostic performance of the new NPC screening scheme, and compare this with other seromarkers.

Materials and Methods
=====================

Study population
----------------

A serological follow-up study of NPC in Zhongshan City, Southern China, which is a high-incidence area of NPC, was conducted. A total of 16,712 individuals, who were 30-59 years old, were recruited between August 2009 and July 2010. A follow-up survey was carried out up to the end of December 2015.

Serologic test and screening protocol
-------------------------------------

Serum samples collected during enrollment and on subsequent occasions, and were tested in separate batches. The samples were stored at 4°C for use within one month, or stored at -80°C for longer periods. Two screening markers, VCA/IgA (Euroimmun, Lubeck, Germany) and EBNA1/IgA (Zhongshan Bio-tech, Zhongshan, China), were tested by ELISA. The levels of these seromarkers were assessed by photometric measurement, according to manufacturers\'instructions, and standardized by calculating the ratio of the optical density (OD) of the sample over that of the reference control (rOD). If the specific rOD was greater than 1, the sample was regarded as positive [@B4].

The new combination of VCA/IgA and EBNA1/IgA was identified, which had a sensitivity of 92.8%, a specificity of 91.6%, and a ROC of 0.97. Then, the prediction formula was developed, as follows: Logit*PROB*= -3.934+2.203 × VCA/IgA +4.797 × EBNA1/IgA [@B5]. On the basis of a predefined serologic algorithm, the participants were classified into three subgroups: high-risk (PROB≥0.98), medium-risk (0.98\>PROB≥0.65), and low-risk (PROB\<0.65). Except for patients diagnosed with NPC, the remaining high-risk and medium-risk subjects were followed-up annually, and blood samples were obtained to examine for EBV-related antibodies. Fiberoptic endoscopy was performed by local otorhinolaryngologists in Zhongshan People\'s Hospital when the serologic result reached the definition of high-risk. Nasopharyngeal biopsies were also performed when suspicious lesions were observed during the endoscopy procedure. Subjects in the low-risk group were reexamined every four years after the initial round of screening. NPC cases were identified by the research team among the high-risk group. As a complement, these cases were identified through linkage to the cancer registries, annually. NPC diagnoses from the low-risk group were mainly ascertained through the cancer registries. NPC was classified according to the World Health Organization classification [@B6], and tumor stage was defined according to the 2008 staging system of China [@B7]. Stage I and II were considered early stages.

Statistical analysis
--------------------

During the screening, subjects with titer EBV antibodies were regarded as observed data, which include true positive a1, false negative b1, false positive c1 and true negative d1. That is, a1 represents NPC patients who are seropositive or high/medium risk subjects, b1 represents NPC patients who are seronegtive or low risk subjects, c1 represents healthy people who are seropositive or high/medium risk subjects, and d1 represents healthy people who are seronegtive or low risk subjects. Based on this notation, the formulas used to calculate for the sensitivity and specificity were as follows: Sensitivity = a1/a1+b1; Specificity = d1/c1+d1; Positive predictive value = a1/a1+c1.

The rates for the early diagnosis of NPC were compared using chi-square tests. The efficacy of EBV antibodies was evaluated using the sensitivity, specificity, positive predictive value (PPV), rate of missed diagnosis, Youden index and AUC. All statistical analyses were two-sided. A *P-*value \<0.05 was considered statistically significant. All analyses were performed using SPSS 20.0 software.

Results
=======

Characteristics of screening participants
-----------------------------------------

Within the first turn of serological screening in 2009 and 2010, 401 and 1,024 out of 16,712 subjects were classified as high-risk and medium-risk, respectively. Thus a total of 1,425 subjects needed to be reexamined for the following two years. In fact, 972 and 623 of these subjects were reexamined in 2011 and 2012, respectively, and compliance decreased from 68.2% to 43.7%. In 2013, 229 and 702 out of 10,801 subjects were classified as high-risk and medium-risk, respectively. Thus, a total of 931 subjects needed to be reexamined for the following two years. In fact, 749 and 502 of these patients were reexamined in 2013 and 2014, respectively, and compliance decreased from 80.5% to 53.9%. During the two screening cycles of the NPC screening (six years), a total of 47 NPC patients were diagnosed from the study subjects. Among these 47 patients, 44 patients, who were classified as high-risk and medium-risk populations, were identified during the routine screening, while three patients, who were classified as a low-risk population, were identified through linkage to cancer registries. As shown in Table [1](#T1){ref-type="table"}, the annual NPC incidences in the 30-59 year-old screening population were very high during the first turn of the serological screening and the first year of follow-up after the initial screening.

Diagnostic values of the new NPC screening scheme (PROB≥0.65) and the other four seromarkers in the preliminary and follow-up study
-----------------------------------------------------------------------------------------------------------------------------------

The sensitivity, specificity and AUC of the individual seromarkers varied between VCA/IgA and EBNA1/IgA, with EBNA1/IgA outperforming VCA/IgA. The sensitivity, specificity, PPV, rate of missed diagnosis, Youden index and AUC was 57.4%, 94.3%, 2.8%, 42.6%, 51.7% and 0.759, respectively, for VCA/IgA, and 76.6%, 96.2%, 5.3%, 23.4%, 72.8% and 0.866, respectively, for EBNA1/IgA.

For the combinations of seromarkers VCA/IgA and EBNA1/IgA, the seropositivity for both VCA/IgA and EBNA1/IgA was considered as a positive screening test result, while the seronegtivity for either VCA/IgA or EBNA1/IgA was considered as a negative result. For VCA/IgA or EBNA1/IgA, the seropositivity for either VCA/IgA or EBNA1/IgA was considered as a positive result, while the seronegtivity for both VCA/IgA and EBNA1/IgA was considered as a negative result. PROB≥0.65 had the highest classification accuracy, with a sensitivity of 95.7%, a specificity of 91.6%, a PPV of 3.1%, a rate of missed diagnosis of 4.3% and a Youden index of 87.3%. The top three seromarkers with the largest AUC were PROB≥0.65 (AUC: 0.926, 95% CI: 0.885-0.966), VCA/IgA or EBNA1/IgA (AUC: 0.883, 95% CI: 0.824-0.942), and EBNA1/IgA (AUC: 0.866, 95% CI: 0.794-0.938) (Table [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}).

Analysis of the rate of early diagnosis for the new NPC screening scheme and the other four seromarkers in NPC screening
------------------------------------------------------------------------------------------------------------------------

The rates of early diagnosis for VCA/IgA, EBNA1/IgA, VCA/IgA and EBNA1/IgA, VCA/IgA or EBNA1/IgA, and PROB≥0.65 were 82.1% (23/28), 74.3% (26/35), 78.3% (18/23), 77.5% (31/40) and 79.5% (35/44), respectively. No significant difference was found in the rate of early diagnosis among the five groups (*P\>*0.05). However, as shown above, PROB≥0.65 can identify the most NPCs (44) and the most early-stage NPCs (35).

Discussion
==========

Zhongshan City in Southern China is one of high-incidence areas of NPC [@B8]. Since the 1980s, the Research Institute of Zhongshan City has launched several pilot efforts to conduct NPC mass screening by measuring two traditional seromarkers, VCA/IgA and IgA antibodies against EBV early antigen (EA/IgA), by using immunofluorescence assay. The limitations of relatively low PPV, lack of a standardized method, high intraobserver variations, and time-consuming protocols make it less applicable in large-scale population screenings [@B9]. A previous study [@B5] used a logistic regression model to identify an optimal biomarker panel to discriminate NPC from controls. It was revealed that the new combination test for VCA/IgA and EBNA1/IgA by ELISA outperformed the traditional NPC screening scheme, in terms of both sensitivity and specificity. The Research Institute of Zhongshan City launched the new serological screening for 16,712 subjects in 2009 and 2010, and a follow-up survey was carried out up to the end of December 2015. The purpose of the present study was to evaluate the long-term diagnostic performance of the new NPC screening scheme, and compare it with other seromarkers.

In the serological screening of the present study, 44 NPC patients were detected in high-risk and medium-risk populations in the two screening cycles. Among these patients, 35 patients were in stage I or II. Furthermore, the rate of early diagnosis was 79.5%, which was significantly higher than those in clinic [@B10]. In the preliminary screening and during the first year of follow-up, the average annual incidence in the cohort was 149.59/10^5^ and 83.90/10^5^, respectively, when compared with the 30-59 year-old general population (29.03/10^5^). This was based on the registered data of the Cancer Institute of Zhongshan City. The screening programme resulted in more diagnosis and early NPCs, when compared to the general population. The overall survival for NPC has increased in recent years [@B11],[@B12]. Hence, prospective randomized trials are needed to provide sound evidence for the potential effect of screening in reducing NPC-specific mortality [@B13].

On the basis of the 6-year follow-up period for the NPC screening, the diagnostic value of the new NPC screening scheme (PROB≥0.65) and the other four seromarkers were investigated by ELISA for NPC detection, including VCA/IgA, EBNA1/IgA, VCA/IgA and EBNA1/IgA, and VCA/IgA or EBNA1/IgA. The results revealed that there was no significant difference in the rate of early diagnosis for EBV seromarkers. For individual seromarkers, the diagnostic performance of EBNA1/IgA was superior to VCA/IgA, with an AUC of 0.866, a PPV of 5.3%, and a specificity of 96.2%. However, its sensitivity was only 76.6%, and the rate of missed diagnosis was unsatisfactory. For the combinations of seromarkers, the diagnostic performance of VCA/IgA or EBNA1/IgA was superior to VCA/IgA and EBNA1/IgA, with a sensitivity of 85.1% and a PPV of 2.6%, leading to unnecessary fiberoptic endoscopy, as well as psychological pressures associated with the procedure. The new NPC screening scheme (PROB≥0.65) resulted in a decrease in missed diagnoses for subjects in the NPC screening, with a sensitivity of 95.7%, a specificity of 91.6%, a PPV of 3.1%, and an AUC of 0.926. This increased the accuracy of the large-scale NPC screening, and can be the preferred serodiagnositc strategy for first turn serological screening and the yearly follow-up.

One of the principles for cancer screening is the follow-up. The screening interval for NPC is a controversial issue that has been inadequately evaluated. Rao DP *et al.* [@B14] constructed a Markov simulation model based on the natural history of NPC to evaluate different screening interval strategies for NPC screening. In the present study, it was found that 93.6% (44/47) NPCs were detected from high-risk and medium-risk populations. Furthermore, the new serological screening was preferable for NPC screening. However, 38 of 44 (86.4%) NPCs were detected during the preliminary serological screening and the first year of follow-up. The NPC detection rate has been dropping significantly ever since.

The present study has several limitations. First, the screening compliance was unsatisfactory. Second, not all high-risk participants underwent nasopharyngeal endosocopy or biopsy, which may cause bias and impact the final results.

In conclusion, the use of a combined test of EBV antibodies by ELISA is recommended to identify NPC patients. The logistic regression model that combined VCA/IgA with EBNA1/IgA was selected to identify the probability of suffering from NPC. It is reasonable to consider that the new serological screening could increase NPC diagnostic accuracy. However, the diagnostic performance has decreased since the first year of follow-up. Future work is warranted to develop a more reasonable screening interval, in order to enhance NPC screening efficiency in the follow-up protocol [@B15].
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###### 

Number of subjects tested and NPC detected during the screening

  Years                                         Total number   No. of high-risk and medium-risk patients   Compliance   No. of patients with NPC   Annual NPC incidence per 100,000 person-year
  --------------------------------------------- -------------- ------------------------------------------- ------------ -------------------------- ----------------------------------------------
  Preliminary screening between 2009 and 2010   16,712         1,425                                       ─            25                         149.59
  Follow-up in 2011                                            972                                         68.2%        14                         65.82
  Follow-up in 2012                                            623                                         43.7%        2                          11.97
  Follow-up in 2013                             10,801         931                                         ─            1                          5.98
  Follow-up in 2014                                            749                                         80.5%        3                          11.97
  Follow-up in 2015                                            502                                         53.9%        2                          5.98

Note: One patient, who was classified as a low-risk population, was identified with NPC through linkage to the cancer registries in 2011, 2013 and 2015, respectively.

###### 

Diagnostic accuracy of individual and combinations of seromarkers

  Group                   Sensitivity   Specificity   Positive predictive value   Rate of missed diagnosis   Youden index
  ----------------------- ------------- ------------- --------------------------- -------------------------- --------------
  VCA/IgA                 57.4%         94.3%         2.8%                        42.6%                      51.7%
  EBNA1/IgA               76.6%         96.2%         5.3%                        23.4%                      72.8%
  VCA/IgA and EBNA1/IgA   48.9%         99.5%         2.3%                        51.5%                      48.4%
  VCA/IgA or EBNA1/IgA    85.1%         90.1%         2.6%                        14.9%                      75.2%
  PROB≥0.65               95.7%         91.6%         3.1%                        4.3%                       87.3%

Positivity for ELISA-based antibodies depended on the rOD value, which was calculated as the ratio of the optical density (OD) value to a reference cutoff OD value simultaneously tested. If rOD was above 1, the specific seromarker was defined as positive. VCA/IgA, IgA antibodies against EBV capsid antigen; EBNA1/IgA, IgA antibodies against EBV nuclear antigen 1.
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